QuidelOrtho Corporation
QuidelOrtho Corporation (QDEL) Financial Performance & Income Statement Overview
Review QuidelOrtho Corporation (QDEL) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
QuidelOrtho Corporation (QDEL) Income Statement & Financial Overview
View the income breakdown for QuidelOrtho Corporation QDEL across both annual and quarterly reports.
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| Revenue | $613.90M | $692.80M | $707.80M | $727.10M |
| Cost of Revenue | $47.90M | $48.00M | $381.70M | $374.80M |
| Gross Profit | $566.00M | $644.80M | $326.10M | $352.30M |
| Gross Profit Ratio | $0.92 | $0.93 | $0.46 | $0.48 |
| R&D Expenses | $45.70M | $53.20M | $47.30M | $55.90M |
| SG&A Expenses | $178.00M | $187.00M | $187.50M | $186.40M |
| Operating Expenses | $223.70M | $240.20M | $426.50M | $337.30M |
| Total Costs & Expenses | $271.60M | $288.20M | $808.20M | $712.10M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $40.50M | $42.30M | $44.70M | $49.90M |
| Depreciation & Amortization | $0.00 | $107.10M | $109.30M | $113.10M |
| EBITDA | $342.30M | $140.60M | $13.10M | $133.80M |
| EBITDA Ratio | $0.56 | $0.20 | $0.02 | $0.18 |
| Operating Income | $342.30M | $32.60M | -$100.40M | $15.00M |
| Operating Income Ratio | $0.56 | $0.05 | -$0.14 | $0.02 |
| Other Income/Expenses (Net) | -$571.90M | -$41.40M | -$40.50M | -$43.80M |
| Income Before Tax | -$229.60M | -$8.80M | -$140.90M | -$28.80M |
| Income Before Tax Ratio | -$0.37 | -$0.01 | -$0.20 | -$0.04 |
| Income Tax Expense | $25.80M | $3.90M | $12.50M | -$8.90M |
| Net Income | -$255.40M | -$12.70M | -$178.40M | -$19.90M |
| Net Income Ratio | -$0.42 | -$0.02 | -$0.25 | -$0.03 |
| EPS | -$3.77 | -$0.19 | -$2.28 | -$0.30 |
| Diluted EPS | -$3.77 | -$0.19 | -$2.28 | -$0.30 |
| Weighted Avg Shares Outstanding | $67.70M | $67.50M | $67.20M | $67.30M |
| Weighted Avg Shares Outstanding (Diluted) | $67.70M | $67.50M | $67.20M | $67.30M |
The company's financials show resilient growth, with revenue advancing from $727.10M in Q3 2024 to $613.90M in Q2 2025. Gross profit remained healthy with margins at 92% in Q2 2025 compared to 48% in Q3 2024. Operating income hit $342.30M last quarter, sustaining a consistent 56% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $342.30M. Net income dropped to -$255.40M, while earnings per share reached -$3.77. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan